FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Sanofi						2. Issuer Name and Ticker or Trading Symbol Inozyme Pharma, Inc. [INZY]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
(Last) 54 RUE I	(Fi DE LA BOI	rst) ETIE	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/28/2020										Officer (give title		Other (s			
(Street) PARIS IO 75008						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(Si	tate)	(Zip)											Person						
		Ta	ıble I - No	on-De	rivati	ve S	ecur	ities Acc	uired	, Dis	sposed of	, or Ben	eficially	Owned						
		Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securitie Disposed O			and 5) Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D)						Price			
Common Stock (par value \$0.0001) 07				07/2	28/202	/2020			С		438,875	A	\$0.00(1)	438,875		I		Through its wholly- owned subsidiary, Aventis Inc.		
Common Stock (par value \$0.0001) 07/28/					28/202	/2020			p ⁽²⁾		81,250	A	\$16 ⁽²⁾	520,125		I		Through ts wholly- owned subsidiary, Aventis nc.		
			Table II								osed of, convertib			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	d 4. Date, Transaction Code (Inst		action	5. Number of Derivative		_	Exercion Da	isable and 7. Title and Amote of Securities		d Amount ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	ve ies ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)					
Series A Convertible Preferred Stock (par value, \$0.0001)	\$0.00 ⁽¹⁾	07/28/2020			С			3,279,720	(1)		(1)	Common Stock	438,875	\$0.00 ⁽¹⁾	C		I	Through its wholly- owned subsidiary, Aventis Inc.		

Explanation of Responses:

Remarks:

/s/ Alexandra Roger, Head of

07/29/2020

Securities Law and Capital Markets

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} On July 28, 2020, Series A Convertible Preferred Stock (par value, \$0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY.

 $^{2. \} The \ reporting \ person \ acquired \ additional \ shares \ in \ the \ Issuer's \ initial \ public \ offering.$

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).